This study showed the potential clinical value of adding known risk factors such as FH, CHEK2 status, PRS311, QRFs, and when available, BD to the validated CanRisk tool in personalized BC risk prediction for unaffected heterozygotes and non-carriers of the CHEK2 variant. Here, CHEK2 is linked to breast cancer.